UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 30,  2008
CERUS CORPORATION
(Exact name of registrant as specified in its charter)

Delaware	 	0-21937	 	68-0262011	
(State of jurisdiction)	 	(Commission File No.)	 	(IRS Employer Identification No.)	
2411 Stanwell Drive
Concord, California 94520
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (925) 288-6000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)	
 
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)	
 
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))	
 
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))	

Item 7.01 Regulation FD Disclosure.
Cerus Corporation (the “Company”) met with staff at the Food and Drug Administration (the “FDA”) on Wednesday, January 30, 2008, to discuss further steps that may lead to U.S. approval of the Company’s INTERCEPT Platelet System. At the meeting, FDA staff indicated that they might consider data from commercial use in Europe as an alternative to an additional large randomized Phase 3 trial. There can be no assurance that Cerus can gather data from commercial use that the Agency would find acceptable.
The information in this Item 7.01 of Form 8-K is “furnished” and not “filed” for the purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act of 1934, except as expressly set forth by specific reference in such filing.

SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	 		 		 	CERUS CORPORATION	
				
Dated: February 1, 2008	 		 	By:	 	/s/ William J. Dawson	
	 		 		 		 	William J. Dawson	
	 		 		 		 	Vice President, Finance and Chief Financial Officer